Verified Panel · Rapidly Mobilized · Trauma-Informed
Research designed for
particular time pressure
Rare oncology and hematologic malignancy research operates under particular time pressure: treatment decisions are urgent, disease trajectories can shift rapidly, and the patient population available for research is shaped directly by treatment response and survival.
MedPanel supports sponsors in this therapeutic area with verified, rapidly mobilized panel access and methodology designed around the realities of active treatment, survivorship, and end-of-life research contexts alike.
Treatment urgency · Population · Emotional stakes
N. America · Europe · Asia-Pacific · LATAM
Diagnosis · Stage · Treatment line
Rapid access for time-sensitive studies
Why Rare Oncology Research Requires a Distinct Approach
Three realities of rare malignancy research — urgency, population dynamics, and emotional stakes — shape how research in this area must be designed.
- Treatment urgency shapes nearly every aspect of design. Patients are frequently engaged in active treatment decision-making at the moment of study recruitment, meaning research must be sensitive to where a participant sits in their treatment journey and avoid imposing burden that competes with clinical priorities.
- Population dynamics differ from chronic rare disease research. The available patient population for a given study is shaped by survival and treatment response patterns specific to the malignancy, and recruitment timelines must account for this rather than assuming a stable population pool over the course of a multi-month study.
- Emotional stakes are often at their highest. This therapeutic area encompasses prognosis uncertainty, treatment decision anxiety, and for some studies, end-of-life or palliative care considerations. MedPanel’s moderators and survey designers apply trauma-informed methodology calibrated specifically to oncology research contexts.
Research Approaches MedPanel Applies in This Therapeutic Area
MedPanel matches methodology to the specific research question, spanning treatment-decision, quality-of-life, caregiver, and survivorship research designs.
Treatment decision and preference research
Treatment decision and preference research helps sponsors understand how patients and physicians weigh efficacy, toxicity, quality of life, and logistical burden when evaluating treatment options for rare malignancies — research that frequently informs both clinical development priorities and patient support program design. MedPanel’s physician and KOL survey and in-depth interview methodologies support this work from both the clinical and patient perspective.
Quality-of-life and symptom burden research
Quality-of-life and symptom burden research captures the impact of both disease and treatment side effects, an area where rare malignancy patients often experience burden profiles distinct from more common cancer types due to less established symptom management protocols. MedPanel’s burden studies practice is structured to capture this distinction.
Caregiver research
Caregiver research is particularly relevant for malignancies with significant functional impact or pediatric incidence, where family caregiving burden runs in parallel with the patient’s own treatment experience. MedPanel’s caregiver studies methodology, including dyad research design, supports studies requiring both perspectives.
Survivorship and long-term outcome research
Survivorship and long-term outcome research extends beyond the active treatment period to capture the lasting impact of rare malignancy diagnosis and treatment — late effects, ongoing monitoring burden, and quality-of-life trajectory after treatment completion. MedPanel’s observational and longitudinal research practice supports the extended timeframes this work requires.
Rapid Mobilization Without Compromising Verification
Oncology timelines are frequently tighter than other rare disease categories — and verification cannot be the cost of moving quickly.
Rare oncology research timelines are frequently tighter than other rare disease categories, driven by competitive development timelines and the urgency of the clinical context. MedPanel’s panel infrastructure is built to mobilize quickly for time-sensitive studies — without relaxing the verification standard that distinguishes our recruitment from self-reported panels.
This verification matters acutely in oncology, where misclassification risk includes not only incorrect diagnosis but incorrect disease stage or treatment line, both of which materially affect the validity of treatment preference and quality-of-life research. MedPanel’s screening protocols confirm diagnosis, stage, and treatment history through physician attestation and medical record review before a participant is included in study recruitment.
MedPanel’s global reach across North America, Europe, Asia-Pacific, and Latin America supports multinational studies, including comparative research across markets with differing access to novel therapies and clinical trial availability — a frequently decisive variable in rare malignancy treatment decision research.
Start your research
Start Your Rare Oncology Research Program
Whether your priority is treatment preference research, quality-of-life evidence, or long-term survivorship tracking, MedPanel’s verified panel and rare disease specialists can mobilize quickly while maintaining the diagnostic precision your study requires.
Panel feasibility confirmed for your target population
Methodology recommended for your timeline and study goals
Rapid mobilization for time-sensitive studies
Verification of diagnosis, stage & treatment line
Contact MedPanel to discuss your research objectives in rare oncology and hematologic malignancies. We will confirm panel feasibility and recommend a methodology suited to your timeline and study goals.